Nearly half of intrahepatic bile duct cancers carry genetic mutations that precision drugs can directly target. A 2026 Cell review puts that figure at 45%, reshaping how oncologists and patients should think about this historically difficult diagnosis. The key is getting genomic testing early.
The 45% Finding Explained
Roughly 45% of intrahepatic cholangiocarcinoma tumors carry genetic alterations that existing or emerging drugs can directly target. These include FGFR2 fusions, IDH1 mutations, ERBB2 alterations, and BRAF mutations. Each represents a molecular vulnerability that precision drugs are engineered to exploit.
The mutations are not evenly distributed. FGFR2 fusions appear in 5% to 10% of cases, while KRAS mutations occur in about 30% of cholangiocarcinoma cases overall. That variation shapes which patients may benefit from which therapy.
It is also worth noting the 45% figure applies most clearly to intrahepatic disease. Extrahepatic bile duct cancers and gallbladder cancers show different mutation landscapes.
What This Means in Practice
Clinical results back up the promise. In eligible patients, the investigational agent lirafugratinib produced an objective response rate of 46.5%, with a median duration of response of 11.8 months. In a cancer where standard chemotherapy yields modest, short-lived benefit, responses measured in many months represent a meaningful shift.
The most concrete step for patients is requesting molecular profiling at diagnosis, not after first-line treatment fails. Specialized hepatobiliary centers are more likely to offer routine profiling and clinical trial access. The 45% figure is a ceiling of current opportunity, not a guarantee, but it is a real one worth pursuing.
